Composite metrics in response assessment-new hope in oesophageal cancer?
pl
dc.type
JournalArticle
pl
dc.description.physical
2786-2787
pl
dc.abstract.en
Oesophageal cancer is still associated with poor prognosis. The progress in systemic treatment, radiation therapy and surgery over the last decades has resulted in only moderate improvement of survival. Neoadjuvant chemoradiotherapy (CRT) has been shown to be associated with tumour response in 60–70% of patients (1), and with complete pathological response (CPR) in 25–30% of patients (2,3). Although it reportedly improves survival, there are several concerns about its routine use. Besides the treatment-related toxicity, the most important issue is lack of reliable predictive factors for pathological tumour and nodal response. In fact, in non-responders the neoadjuvant therapy is harmful, as it delays alternative, potentially effective treatment. Progression during the neoadjuvant therapy is not rare in this subset of patients.
pl
dc.description.volume
9
pl
dc.description.number
9
pl
dc.description.points
20
pl
dc.identifier.doi
10.21037/jtd.2017.08.28
pl
dc.identifier.eissn
2077-6624
pl
dc.title.journal
Journal of Thoracic Disease
pl
dc.language.container
eng
pl
dc.affiliation
Wydział Nauk o Zdrowiu : Instytut Fizjoterapii
pl
dc.subtype
OtherDocuments
pl
dc.rights.original
CC-BY-NC-ND; otwarte czasopismo; ostateczna wersja wydawcy; w momencie opublikowania; 0
Except where otherwise noted, this item's license is described as Udzielam licencji. Uznanie autorstwa - Użycie niekomercyjne - Bez utworów zależnych 4.0 Międzynarodowa